Image source: Getty Images.
Forty-three million Americans are at risk of suffering a life-threatening allergic reaction, and the vast majority of people who suffer one turn to Mylan N.V.‘s (NASDAQ: MYL) EpiPen to halt it in its tracks. The EpiPen’s lifesaving nature makes it a must-have in patient purses and backpacks, but a long record of price hikes has landed the generic giant on the hot seat.